Mukka Proteins to acquire remaining 25.99% stake in Ento Proteins for ₹32.3 Lakhs
Mukka Proteins Limited will acquire the remaining 25.99% equity in Ento Proteins Private Limited for ₹32.3 Lakhs. This move will increase Mukka Proteins' stake to 100%. The transaction is set for completion following the execution of the Share Purchase Agreement on February 21, 2026.
The acquisition of a subsidiary, especially acquiring the remaining stake, is a significant corporate action that can impact future earnings and strategic direction. However, the transaction value is relatively small compared to the overall size of the company.
The company is acquiring full ownership of a subsidiary, which is generally a positive strategic move for consolidating control and operations.
Mukka Proteins Limited has entered into a Share Purchase Agreement (SPA) on February 21, 2026, to acquire the remaining 25.99% equity share capital of its investee company, Ento Proteins Private Limited. This acquisition is from Holocene Ecosolutions Private Limited, a shareholder in Ento Proteins.
The total consideration for this acquisition is ₹32,30,000 (Indian Rupees Thirty-Two Lakhs Thirty Thousand only). Mukka Proteins currently holds 74.01% of Ento Proteins. With this acquisition, the company will own 100% of the investee company.
As part of the agreement, the Shareholders' Agreement dated September 7, 2021, and its amendments will be rescinded and terminated effective from the closing date. The promoters of Mukka Proteins Limited are also directors of Ento Proteins Private Limited, but the transaction is not considered a related party transaction. The acquisition involves 1,000 equity shares of face value ₹100 each.
What to do with a filing like this
Mukka Proteins Limited filed this with the NSE as a statutory disclosure, categorised under acquisition. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Mukka Proteins Limited. Read the original for the full detail.